Recommendation to revise the AJCC/UICC breast cancer staging system for inclusion of proven prognostic factors: ER/PR receptor status and HER2 neu. - Suppr | 超能文献

Recommendation to revise the AJCC/UICC breast cancer staging system for inclusion of proven prognostic factors: ER/PR receptor status and HER2 neu.

作者信息

Murthy Vijayashree, Chamberlain Ronald S

出版信息

Clin Breast Cancer. 2011 Oct;11(5):346-7. doi: 10.1016/j.clbc.2011.05.003. Epub 2011 Aug 5.

DOI:10.1016/j.clbc.2011.05.003

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Recommendation to revise the AJCC/UICC breast cancer staging system for inclusion of proven prognostic factors: ER/PR receptor status and HER2 neu.

Clin Breast Cancer. 2011 Oct;11(5):346-7. doi: 10.1016/j.clbc.2011.05.003. Epub 2011 Aug 5.

2

Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.激素受体、人表皮生长因子及其与阿尔巴尼亚乳腺癌肿瘤特征的关联

Cent Eur J Public Health. 2016 Sep;24(3):171-175. doi: 10.21101/cejph.a4085.

3

Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.T1、T2 和 T3 期肿瘤中淋巴结阴性、ER/PR/HER2 阳性乳腺癌亚型的死亡风险。

Breast Cancer Res Treat. 2017 Oct;165(3):743-750. doi: 10.1007/s10549-017-4383-5. Epub 2017 Jul 8.

4

Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experience.在生物标志物和乳腺癌新兴个性化医疗时代，乳腺癌的TNM分期系统是否仍然适用——一家机构的10年经验

Breast J. 2015 Mar-Apr;21(2):147-54. doi: 10.1111/tbj.12367. Epub 2015 Jan 20.

5

Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.导管浸润性乳腺癌——与激素受体和Her2/neu癌蛋白免疫组化表达相关的临床病理预后因素

Rom J Morphol Embryol. 2011;52(3 Suppl):1059-64.

6

Age related influence of triple receptor status on metastatic breast cancer post relapse survival.三受体状态对转移性乳腺癌复发后生存的年龄相关影响。

J BUON. 2013 Oct-Dec;18(4):851-8.

7

The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis.美国癌症联合委员会（AJCC）第8版分期系统在HER2富集亚型乳腺癌中的预后价值：一项回顾性分析

Anticancer Res. 2017 Aug;37(8):4615-4621. doi: 10.21873/anticanres.11862.

8

Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.免疫组织化学鉴定浸润性乳腺癌的分子亚型：来自印度北部的一项研究。

APMIS. 2012 Dec;120(12):1008-19. doi: 10.1111/j.1600-0463.2012.02933.x. Epub 2012 Jul 26.

9

Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.土耳其东南部不同种族乳腺癌患者的激素受体及HER2状态

J BUON. 2013 Jul-Sep;18(3):619-22.

10

Do we need HER-2/neu testing for all patients with primary breast carcinoma?对于所有原发性乳腺癌患者，我们都需要进行HER-2/neu检测吗？

Cancer. 2003 Dec 15;98(12):2547-53. doi: 10.1002/cncr.11828.

引用本文的文献

1

Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.炎性乳腺癌：国际抗癌联盟（UICC）-美国癌症联合委员会（AJCC）TNM分期系统中提议的概念转变

Lancet Oncol. 2017 Apr;18(4):e228-e232. doi: 10.1016/S1470-2045(17)30192-4.

2

Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.17号染色体多体对浸润性乳腺癌患者HER2检测的影响。

Int J Clin Exp Pathol. 2013 Dec 15;7(1):163-73. eCollection 2014.

3

Radiation therapy following surgery for localized breast cancer: outcome prediction by classical prognostic factors and approximated genetic subtypes.局部乳腺癌手术后的放射治疗：经典预后因素和近似遗传亚型的预后预测。

J Radiat Res. 2013 Mar 1;54(2):292-8. doi: 10.1093/jrr/rrs087. Epub 2012 Sep 26.